Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$713K Buy
2,727
+79
+3% +$20.3K 0.31% 70
2026
Q2
$666K Buy
2,648
+102
+4% +$21.9K 0.3% 72
2026
Q1
$554K Buy
2,546
+118
+5% +$26.2K 0.28% 74
2025
Q4
$555K Buy
2,428
+8
+0.3% +$1.82K 0.28% 74
2025
Q3
$560K Buy
2,420
+10
+0.4% +$2.04K 0.3% 70
2025
Q2
$447K Sell
2,410
-14
-0.6% -$2.6K 0.26% 74
2025
Q1
$508K Buy
2,424
+81
+3% +$15.7K 0.32% 72
2024
Q4
$416K Sell
2,343
-14
-0.6% -$2.57K 0.26% 79
2024
Q3
$465K Buy
2,357
+43
+2% +$8.02K 0.29% 69
2024
Q2
$397K Buy
2,314
+23
+1% +$3.81K 0.26% 71
2024
Q1
$417K Buy
2,291
+18
+0.8% +$3.1K 0.29% 69
2023
Q4
$352K Buy
2,273
+51
+2% +$7.44K 0.26% 75
2023
Q3
$331K Buy
2,222
+27
+1% +$3.96K 0.27% 77
2023
Q2
$296K Buy
2,195
+1
+0% +$147 0.23% 81
2023
Q1
$350K Sell
2,194
-52
-2% -$7.95K 0.29% 76
2022
Q4
$363K Buy
2,246
+55
+3% +$8.43K 0.3% 74
2022
Q3
$294K Sell
2,191
-3
-0.1% -$430 0.27% 76
2022
Q2
$336K Buy
2,194
+13
+0.6% +$1.99K 0.29% 73
2022
Q1
$353K Buy
2,181
+194
+10% +$28.2K 0.27% 77
2021
Q4
$269K Buy
+1,987
New +$235K 0.2% 86

Other funds holding ABBV

W Advisors's ABBV Position: Q3 2026 in Review

W Advisors increased its AbbVie (ABBV) stake by 3% in Q3 2026, buying an estimated $20.3K and bringing the position to 2,727 shares worth $713K. The position accounts for 0.31% of the portfolio, ranked #70.

W Advisors first reported a position in ABBV in Q4 2021 and has held it in 20 quarters since. 3,876 funds tracked by Wall St. Rank hold ABBV as of Q3 2026.

  • W Advisors held 2,727 shares of AbbVie worth $713K as of Q3 2026.
  • W Advisors bought 79 AbbVie shares in Q3 2026, an estimated $20.3K.
  • AbbVie made up 0.31% of W Advisors's portfolio in Q3 2026, its #70 holding.
  • W Advisors first reported a position in AbbVie in Q4 2021 and has held it in 20 quarters since.
  • 3,876 funds tracked by Wall St. Rank held AbbVie as of Q3 2026.

Based on W Advisors's 13F filing for Q3 2026, filed 2 Nov 2026.